Innovating Works

TLS

Desconocido
PROACTIVE: PROposing Action to ConTrol and Impede betacoronaVirus Emergencies FONDAZIONE TOSCANA LIFE SCIENCES tramitó un HORIZON EUROPE: ERC-2022-ADG The COVID-19 pandemic caught the world unprepared. Vaccines and monoclonal antibodies (mAbs), developed in record time, mitigated the health...
2023-10-31 - 2028-10-31 | Financiado
ArTCell: Bottom-up manufacturing of artificial anti-tumor T cells FONDAZIONE TOSCANA LIFE SCIENCES participó en un HORIZON EUROPE: HORIZON-EIC-2023-PATHFINDEROPEN-01 T cells play a central role in anti-tumor immune protection. While their ability to target and eliminate emerging tumor cells is increasingl...
2023-10-09 - 2029-01-31 | Financiado
MammoScreen: Innovative and safe microwave-based imaging technology to make breast cancer screening more accurate... FONDAZIONE TOSCANA LIFE SCIENCES tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Breast cancer (BC) is the most common cancer in women worldwide, affecting 1 in 8 women. The figures from WHO’s International Agency for Res...
2022-11-28 - 2026-11-30 | Financiado
BornToGetThere: Implementation of early detection and early intervention service delivery in infants at risk for cer... FONDAZIONE TOSCANA LIFE SCIENCES participó en un H2020: H2020-SC1-BHC-2018-2020 Despite advances in the medical management of high-risk pregnancies and deliveries, cerebral palsy (CP) remains the most common physical dis...
2019-12-10 - 2024-12-31 | Financiado
SINO-EU-PerMed: Widening Sino EU policy and research cooperation in Personalised Medicine FONDAZIONE TOSCANA LIFE SCIENCES participó en un H2020: H2020-SC1-BHC-2018-2020 Personalised Medicine (PerMed) approaches bring along immense potentials to improve diagnosis and treatment of diseases and prevention strat...
2019-12-02 - 2024-06-30 | Financiado
VACCIBIOME: Cancer Vaccines and Gut Microbiome a rational approach to optimize cancer immunotherapy FONDAZIONE TOSCANA LIFE SCIENCES participó en un H2020: ERC-2018-ADG This proposal intends to shed light on the interplay between cancer immunity and gut microbiome as a way to optimize personalized cancer vac...
2019-06-04 - 2024-08-31 | Financiado
REGIONS4PERMED: INTERREGIONAL COORDINATION FOR A FAST AND DEEP UPTAKE OF PERSONALISED HEALTH FONDAZIONE TOSCANA LIFE SCIENCES tramitó un H2020: H2020-SC1-BHC-2018-2020 Personalised medicine (PM) represents a paradigm shift away from a ‘one size fits all’ approach to the treatment and care of patients with a...
2018-10-19 - 2023-04-30 | Financiado
vAMRes: Vaccines as a remedy for antimicrobial resistant bacterial infections FONDAZIONE TOSCANA LIFE SCIENCES tramitó un H2020: ERC-2017-ADG Antimicrobial Resistance (AMR) is perhaps the most emerging alarm in health. It already causes 700,000 deaths per year and the forecast for...
2018-09-04 - 2023-10-31 | Financiado
OMVCRC: Engineered bacterial Outer Membrane Vesicles OMVs for colorectal cancer immunotherapy FONDAZIONE TOSCANA LIFE SCIENCES participó en un H2020: ERC-2017-PoC This proposal originates from recent results obtained in the course of the Advanced ERC Project OMVac, the scope of which is to exploit the...
2017-11-07 - 2019-06-30 | Financiado
TRANSCAN-2: ERA NET Aligning national regional translational cancer research programmes and activities Cancer is a worldwide health burden and represents a major public health challenge in Europe. It is responsible for 25% of all deaths, being...
2014-12-01 - 2021-06-30 | Financiado
NERRI: Neuro Enhancement Responsible Research and Innovation FONDAZIONE TOSCANA LIFE SCIENCES participó en un FP7: This project aims to contribute to the introduction of Responsible Research and Innovation in neuro-enhancement (NE) in the European Researc...
Financiado
EPISODE: Exploiting the Potential of Structural Biology through NMR and Associated Technologies Opportuniti... FONDAZIONE TOSCANA LIFE SCIENCES participó en un FP7: EPISODE’s goal is to maximize the regional benefits of Structural Biology Research Infrastructures in NMR and associated technologies for th...
Financiado
OMVAC: Outer Membrane Vesicles OMVs from Vaccinobacter A Synthetic Biology approach for effective vacc... FONDAZIONE TOSCANA LIFE SCIENCES participó en un FP7: This proposal intends to apply Synthetic Biology to create a new bacterial species, Vaccinobacter, devoted to the production of multivalent,...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.